Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted ...

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat ...

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment ...

Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and ...

The San Diego start-up has three candidates targeting PARP1, one of a family of enzymes that is already a validated target in ovarian, breast, prostate and pancreatic cancers with approved ...

AZ has been presenting preclinical data from AZD5305, its next-generation PARP1 inhibitor at the 2021 American Association for Cancer Research meeting, which the company thinks could be more ...

Poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair, and inhibition of PARP1 specifically drives synthetic lethality in BRCA-mutated disease. While they have achieved commercial success, ...